



(P.W)  
1625

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT  
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON

July 28, 2005

May J. Jensen  
ATTORNEY FOR APPLICANT

July 28, 2005

DATE

Attorney Docket No. P32286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackler et al. July 28, 2005

Serial No.: 10/019,355 Group Art Unit No.: 1625

Filed: March 22, 2002 Examiner: P.L. Morris

For: Thiazolidinedione Derivative and Its Use as Antidiabetic

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449.

Copies of each are enclosed.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

08/02/2005 HMARZI1 00000018 192570 10019355  
01 FC:1806 180.00 DA

Serial No.: 10/019,355  
Group Art Unit No.: 1625

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090  
n:\cls\cases\p32286\supplementalids.doc



Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32286	SERIAL NO. 10/019,355
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Blackler et al.	
		FILING DATE March 22, 2002	GROUP 1625

#### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes <input type="checkbox"/> No <input type="checkbox"/>
	WO 01/82867	11/8/01	PCT			

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Phadnis et al., Identification of Drugs in Pharmaceutical Dosage Forms by X-Ray Powder Diffractometry, <i>Journal Pharmaceutical and Biomedical Analysis</i> , Vol. 15, pp. 929-943 (1997)
	Chakravarty et al., Crystal Forms of Tolbutamide from Acetonitrile and 1-Octanol: Effect of Solvent, Humidity and Compression Pressure, <i>International Journal of Pharmaceutics</i> , Vol. 288, pp. 33-348 (2005)
	Cantello et al., The Synthesis of BRL49653 – A Novel and Potent Antihyperglycaemic Agent, <i>Bioorganic &amp; Medical Chemistry Letters</i> , Vol. 4, No. 10, pp. 1181-1184 (1994)
	Concise Encyclopedia Chemistry, pp. 872-873 (1993)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.